Amgen Inc.

Biovitrum Ab

Array Biopharma Inc.

Christopher Harold Fotsch

Mark Henry Norman

Nianhe Han

Qingyian Liu

Ning Chen

Xianghong Wang

Chester Chenguang Yuan

Elizabeth M Doherty

Vassil I Ognyanov

Jiawang Zhu

Celia Dominguez

Markian Myroslaw Stec

Aiwen Li

Ning Xi

Partha P Chakrabarti

Michael G Kelly

Liping H Pettus

Shimin Xu

Hui-Ling Wang

Michael D Bartberger

David Joseph St Jean, Jr

Christopher Michael Tegley

Randall W Hungate

Yunxin Y Bo

Lars Johansson

Kevin Chao Yang

Guolin Cai

John Gordon Allen

Qi Huang

Paul E Harrington

Meredith Williams

Evert Homan

George Moniz

Martin Henriksson

Eric A Bercot

Matthew J Frizzle

Premilla Arasasingham

Andrew Stewart Tasker

Jian Jeffrey Chen

Robert Michael Rzasa

Longbin Liu

Nuria A Tamayo

Matthew Paul Bourbeau

Qingping Zeng

James Richard Falsey

Thomas Nixey

Fang-Tsao Hong

Derin C D'amico

Matthew Lee

Seifu Tadesse

Guomin Yao

Rana Nomak

Xin Huang

Babak Riahi

Christopher Hulme

Jodie Katon

Thomas T Nguyen

Scott S Harried

Vu Van Ma

Wenyuan Qian

Robert D Groneberg

Michael D Croghan

Kaustav Biswas

Thomas Stephen Coulter

Vijay Keshav Gore

Benny C Askew, Jr

Chiara Ghiron

Steve Fong Poon

Chenera Balan

James Zhan

James Thomas Rider

George Erich Wohlhieter

Kurt E Weiler

Vellarkad N Viswanadhan

Ofir A Moreno

Yi-xin Qian

Ben C Askew

Nobuko Nishimura

Michael J Frohn

Alexander J Pickrell

David A Mareska

Lewis D Pennington

Gilbert M Rishton

Sarah Lively

Andreas Reichelt

Marianne Nilsson

Roxanne Kay Kunz

Pierre Deprez

Andras Toro

Marian C Bryan

Kate Ashton

Lori Sutin

Martin Haraldsson

Mirna Mujacic

Tanya Peterkin

Kanaka Pattabiraman

Youngboo Kim

Philip Miller

Teresa L Marshall

David J Semin

Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein. 

Carbohydrate phosphonate derivatives as modulators of glycosylation

The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula (I). Where Cyis pyridinonyl, pyridinyl, quinolinyl or 9-ethyl-9H-beta-carbolinyl, each of which optionally substituted and where Cyis phenyl naphthyl. 

Calcium receptor modulating agents

The present invention relates to compounds with the formula (I), (II), (III) or (IV): 

Inhibitors of 11-&#x3b2;-hydroxy steroid dehydrogenase type 1

The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-&#x3b2;-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-&#x3b2;-hydroxysteroid dehydrogenase type 1 enzyme.

Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Compounds that interact with glucokinase regulatory protein for the treatment of diabetes

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes. 

The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I. 

Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein. 

Thiazole compounds and methods of use

Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotizing agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Thiadiazole modulators of PKB

Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder: wherein the variables A-B, R, R, m, and Q are described herein.

Substituted azole aromatic heterocycles as inhibitors of 11&#x3b2;-HSD-1

Therapeutic benzimidazoles having the general structure: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Growing community of inventors

Thousand Oaks, CA, United States of America

Christopher Harold Fotsch